Evelo Biosciences Inc

NASDAQ:EVLO   3:59:50 PM EDT
7.98
-0.15 (-1.84%)
Products, Strategic Combinations

Evelo Biosciences, Abdul Latif Jameel Health Announce Strategic Collaboration

Published: 03/23/2021 08:21 GMT
Evelo Biosciences Inc (EVLO) - Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration .
Collaboration to Develop and Commercialize Evelo’s Lead Inflammation Product Candidate Edp1815 in the Middle East, Turkey, and Africa.
The Company is Also Conducting a Phase 2 Clinical Trial for Edp1815 in Psoriasis, As Well As Two Trials in Patients Hospitalized With Covid-19.
Together, Evelo and Abdul Latif Jameel Health Will Work to Address the Significant Disparity in Access to Medical Care in the Fastest-growing Populations and Growth Economies of the Developing World.
Under the Terms of the Agreement, Evelo Received an Upfront Payment and Equity Investment.
Evelo Will Be Responsible for the Development and Manufacturing of Edp1815, Whilst Abdul Latif Jameel Health Will Be Responsible for Regulatory Submissions and Commercialization Activities in the Agreed-upon Regions.
Evelo and Abdul Latif Jameel Health Will Participate in a 50:50 .
Further Company Coverage: Evloo ((reuters.
Briefs@thomsonreuters.
Com;)).